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Abstract 
A multicenter cross‐sectional study was conducted to determine the current heart transplant (HTx) outcomes 
in Spain. Clinical and functional status, health‐related quality of life (HRQoL), social support, and caregiver 
burden were analyzed in 303 adult transplant recipients (77.9% males) living with one functioning graft. 
Mean age at time of HTx (SD) was 56.4 (11.4) years, and the reason for transplantation in all patients was 
congestive heart failure. All patients had received a first heart transplant 6 (±1), 12 (±2), 36 (±6), 60 (±10), or 
120 (±20) months previously. Participants completed the Kansas City Cardiomyopathy Questionnaire 
(KCCQ), the EQ‐5D, the Duke‐UNC Functional Social Support Questionnaire, and the Zarit Caregiver 
Burden Scale. Reasonable HRQoL, social support, and caregiver burden levels were found at all time points, 
although a slight decrease in HRQoL was recorded at 120 months (p ≤ 0.033). Multivariate regression 
analyses showed that complications, comorbidities, and hospitalizations were associated with HRQoL (EQ‐
5D: 48.4% of explained variance, F4,164 = 38.46, p < 0.001; KCCQ overall summary score: 45.0%, 
F3,198 = 54.073, p < 0.001). Patient functional capabilities and complications affected caregiver burden 
(p < 0.05). In conclusion, HTx patients reported reasonable levels of HRQoL with low caregiver burden. 
Clinical variables related to these outcomes included functional status, complications, and number of 
admissions. 




The main goals of heart transplantation are to increase the life span of patients with advanced 
heart disease and to optimize their health‐related quality of life (HRQoL), especially when these 
benefits cannot be guaranteed with the medical treatments available. The clinical effectiveness of 
heart transplantation is analyzed by comparing outcomes with those of other medical procedures, 
in terms of both survival rates (1-3) and patient‐reported outcomes (PRO) (4). One of the most 
commonly used PRO measures is HRQoL, which can be defined as follows: “The value assigned 
to duration of life as modified by the impairments, functional states, perceptions, and social 
opportunities that are influenced by disease, injury, treatment, or policy (5).” Evidence from 
research has shown that patients' HRQoL after allograft improves in comparison with their 
situation before surgery (6-8). Furthermore, these benefits continue for as long as 5–10 yr post‐
transplant (9, 10). According to the HRQoL definition cited above, several factors can influence 
recipient HRQoL, including sociodemographic variables, work status, comorbidities, episodes of 
acute rejection, hospitalizations, side effects of medication, patient personality, and others (6), (10-
14). Thus, this study examined the effect of the following factors on patient HRQoL, six, 12, 36, 
60, and 120 months after receiving the allograft: clinical and functional status of recipients, social 
support, work situation, employment rates, and caregiver burden. Furthermore, patient HRQoL 
was evaluated by applying disease‐specific and generic patient‐reported outcomes measures, as 
recommended in the guidelines (15), to adequately assess the impact of disease on HTx patients 
while allowing comparisons with other populations. This information is of interest, given the fact 
that, despite the excellent survival rates reported in Spain (2, 3), short and, especially, long‐term 
results for variables related to patient HRQoL have not yet been comprehensively addressed.  
Methods 
Study population 
Heart transplant patients attending programmed cardiology visits were invited to participate in 
this multicenter, epidemiological, cross‐sectional study. Between December 2010 and December 
2011, data were collected by cardiologists from the 14 reference centers for organ transplantation 
in Spain. Patients who agreed to participate and met the selection criteria were recruited: adult 
recipients (aged ≥18) living with a single functioning graft, who had received a first heart 
transplant due to congestive heart failure, six (±1), 12 (±2), 36 (±6), 60 (±10), or 120 (±20) months 
before the interview. Multiple solid organ transplant or retransplant recipients were excluded. All 
patients were enrolled after providing written informed consent prior to the start of the study, 
which was conducted in accordance with the Declaration of Helsinki and Good Clinical Practice 
guidelines. The study protocol and case report form were approved by the Clinical Research Ethics 
Committee of the Hospital Universitario 12 de Octubre (Madrid, Spain). Data collection was 
conducted by a specially trained clinical monitor, under the supervision of the study coordinator 
(JFD). All data were entered in an electronic database installed in a secure server using numerical 
codes for the investigators and patients at each site. 
  
Procedure 
Clinical data related to patient health status immediately before transplantation were retrieved 
from the medical records: age, sex, body mass index (BMI), heart disease that led to transplant 
(acute/chronic heart failure), indication (elective/urgent), and underlying heart disease (idiopathic 
dilated cardiomyopathy/ischemic cardiomyopathy/valvular cardiomyopathy/other). 
 
Additionally, investigators evaluated the clinical status of participants at the time of the 
consultation, according to the following variables: New York Heart Association (NYHA) 
functional classification, left ventricular ejection fraction (by echocardiogram), resting heart rate, 
number of acute rejections recorded, number of biopsies after transplant, chronic oral 
anticoagulant treatment, number of hospital admissions (not scheduled), and infectious diseases 
(requiring medical treatment). The presence of coexisting complications or additional diseases was 
assessed by means of the Charlson Comorbidity Index. In addition, specific comorbidities were 
classified into several dichotomous variables (“yes” or “no”): high blood pressure; hyperlipidemia; 
malignancy (cutaneous malignancy, lymphomas, or other solid or hematological malignancies); 
and dermatological, urological, neuromuscular, and orthopedic diseases. 
 
During the single study visit, patients were asked for information about their personal situation 
(living situation, marital status, work status, and educational level) at two time points: immediately 
before transplant and at the time of the interview. Satisfaction with their current work status was 
reported only by patients who were not retired at the time of the interview. 
Patient‐reported outcomes 
Patient‐reported outcomes were determined by the use of the following questionnaires: 
EQ‐5D‐3L (16) 
This generic instrument allows investigators to obtain valid information about patient HRQoL 
and community preference‐based values (or utilities) related to all possible health states described 
(n = 243). The EQ‐5D utility index in Spain ranges from −0.654 (worst possible health status) to 1 
(completely healthy). Furthermore, the EQ‐5D descriptive system encompasses five different 
domains (mobility, self‐care, usual activities, pain/discomfort, and anxiety/depression). A visual 
analog scale (VAS) that ranges from 0 (worst state) to 100 (perfect health) is also used to 
determine patients' perceived HRQoL at the time of the interview. 
Kansas City Cardiomyopathy Questionnaire (KCCQ) (17) 
This instrument was developed to assess HRQoL in patients with chronic heart failure and has 
been successfully used in heart transplant patients. This disease‐specific instrument comprises 23 
items (five‐ to seven‐point Likert scale items) assessing six domains: physical limitations, 
symptoms, symptom stability, social limitation, self‐efficacy, and quality of life (QoL). In 
addition, two summary scores can be calculated: the overall summary score (OSS) and the clinical 
summary score (CSS). Domain scores can be easily converted into scales ranging from 0 (worst 
level) to 100 (highest level). 
  
Duke‐UNC Functional Social Support Questionnaire (18) 
This brief scale (11 items with five response levels) was developed with the purpose of 
measuring the strength of the respondent's social support network. Scores range from 11 (lowest 
level of social support) to 55 (highest level). A score of ≥32 indicates a normal social network. 
 
In addition, caregiver burden was assessed using Zarit Caregiver Burden Interview (19), a self‐
administered instrument comprising 22 items on a five‐point Likert scale. It was completed by the 
closest relative or caregiver of each patient, to determine the impact of the patient's condition on 
their own life and their feelings of stress or burden. Scoring ranges from 0 (lowest burden) to 88 
(highest burden).  
Statistical analysis 
Participants were classified into five independent groups according to time since transplant: six 
(±1), 12 (±2), 36 (±6), 60 (±10), or 120 (±20) months, and a descriptive analysis of their 
sociodemographic and clinical variables was performed (frequencies and percentages for 
qualitative variables and measures of central tendency, dispersion and normality for quantitative 
variables). Differences in categorical variables among the groups were tested by applying the chi‐
square test or the Fisher's exact test in case of 2 × 2 tables or <20 valid cases. For quantitative 
variables, differences were compared using the Kruskal–Wallis test with the Mann–Whitney U‐
test (with Bonferroni's correction for multiple comparisons). Multivariate regression analyses 
(stepwise methods with enter and exit criteria of 0.05 and 0.1, respectively) were carried out to 
study possible relationships between predictor (independent) variables (comorbidities and other 
clinical and sociodemographic variables) and criterion (dependent) variables (questionnaires: 
patient HRQoL, social support, and caregivers' feeling of burden). The following variables were 
entered in the models: time since transplant (6 ± 1, 12 ± 2, 36 ± 6, 60 ± 10, or 120 ± 20 months), 
age, sex, marital status, living and work situation, educational level, presence of complications, 
NYHA classification, resting heart rate, number of acute rejections, number of biopsies after 
transplant, chronic oral anticoagulant treatment, number of unscheduled hospital admissions, and 
infectious diseases (requiring medical treatment). The possible multicollinearity between 
regression model parameters was considered by examining tolerance and the variance inflation 
factor.  
 
The sample size was calculated with the aim of finding moderate differences in the outcome 
measures described above (effect size of 0.5) using pairwise comparisons among independent 
groups, with a Type I error of 0.05 and a power (1‐ß) of 0.8 (one‐tailed). Thus, the minimum 
sample size in each group was set at 51 patients. For two‐tailed tests, a minimum of 64 patients per 
group would be required to have the same Type I error probability and statistical power. 
 
SPSS (version 16.0) and Stata 10 (StataCorp, College Station, TX, USA) statistical packages 
were used to conduct all analyses. 
  
Results 
Sociodemographic and clinical characteristics 
A total of 350 heart transplant patients were formally invited to participate in the study, and 
data were collected from those who agreed to be interviewed and met the selection criteria 
(n = 331, 94.57%). However, after a quality control check of the database, a small proportion 
(8.46%, n = 28) had to be withdrawn from the analysis because they do not meet the inclusion 
criteria in terms of time since transplant. Thus, a final sample of 303 transplant recipients (77.9% 
males) with a mean age (SD) of 56.4 (11.4) yr was included in the analyses. As stated above, all 
participants were allocated to five different groups according to time since transplant. Moreover, 
240 caregivers completed the Zarit Caregiver Burden Interview (97.3% were close relatives and 
2.7% professional caregivers). Sociodemographic and clinical variables are presented in Tables 1-
3.  
Table 1. Sample description: sociodemographic variables at interview time 
 6 months 
(n = 52) 
 12 months 
(n = 57) 
 36 months 
(n = 66) 
 60 months 
(n = 62) 
 120 months 
















Alone 3 5.8  4 7.0  12 18.2  3 4.8  7 10.6  0.021 
Family 47 90.4  53 93.0  54 81.8  58 93.5  59 89.4  
Institution 2 3.8  0 0.0  0 0.0  0 0.0  0 0.0  
Marital status 
Single 8 15.4  8 14.0  5 7.6  7 11.3  3 4.5  0.213 
Couple/Married 39 75.0  42 73.7  48 72.8  52 83.9  55 83.3  
Widow/er 2 3.8  2 3.5  2 3.0  0 0.0  4 6.1  
Separated/Divorced 2 3.8  4 7.1  10 15.2  3 4.8  4 6.0  
Work status 
Full time 4 7.7  1 1.8  4 6.1  7 11.3  7 10.6  0.630 
Part time 3 5.8  3 5.3  1 1.5  2 3.2  0 0.0  
Retired 4 7.7  9 15.8  8 12.1  9 14.5  5 7.6  
Retired due to 
disease 
31 59.6  38 66.7  42 63.6  36 58.1  41 62.1  
Unemployed 8 15.4  6 10.5  10 15.2  7 11.3  8 12.1  
Employed 
Yes 7 13.5  4 7.0  5 7.6  9 14.5  7 10.6  0.571 
                 
 
HTx, heart transplant.  




Table 2. Clinical characteristics of heart recipients: categorical variables 
 
6 months 
(n = 52) 
 
12 months 
(n = 57) 
 
36 months 
(n = 66) 
 
60 months 
(n = 62) 
 
120 months 




n %  n %  n %  n %  n %  
 
Sex 
Male 37 71.2  48 84.2  51 77.3  49 79.0  51 77.3  0.597 
Disease inducing HTx 
Chronic 46 88.5  54 94.7  63 95.5  55 88.7  61 92.4  0.534 
Acute 5 9.6  3 5.3  3 4.5  7 11.3  4 6.1  
Acute stroke 2 3.8  2 3.5  3 4.5  4 6.5  6 9.1  
Inflam. disease 3 5.8  0 0.0  3 4.5  2 3.2  1 1.5  
Type of HTx 
Elective 39 75.0  46 80.7  53 80.3  46 74.2  57 86.4  0.499 
Urgent 12 23.1  11 19.3  13 19.7  16 25.8  9 13.6  
Underlying heart disease at HTx 
Dilated 
Idiopathic 
23 44.2  19 33.3  32 48.5  26 41.9  29 43.9  0.108 
Ischemic 18 34.6  24 42.1  17 25.8  20 32.3  32 48.5  
Valvular 3 5.8  7 12.3  8 12.1  6 9.7  2 3.0  
Other 8 15.4  7 12.3  7 10.6  10 16.1  2 3.0  
NYHA functional at interview 
Class I 45 86.5  48 84.2  58 87.9  53 85.5  42 63.6  0.005 
Class >I 7 13.5  9 15.8  8 12.1  9 14.5  24 36.4  
Class II 7 13.5  7 12.3  5 7.6  8 12.9  22 33.3  
Class III 0 0.0  2 3.5  3 4.5  1 1.6  2 3.0  
NYHA objective at interview 
Class A 42 80.8  47 82.5  55 83.3  52 83.9  44 66.7  0.065 
Class>A 10 19.2  10 17.5  11 16.7  9 14.5  22 33.3  
Resting heart rate at interview 
S. Tachycardia 41 78.8  48 84.2  48 72.7  55 88.7  52 78.8  0.348 
Rhythm P. 1 1.9  1 1.8  4 6.1  1 1.6  5 7.6  
Immunosuppressive treatment: Steroids have been withdrawn (at interview) 
Yes 1 1.9  8 14.0  15 22.7  12 19.4  21 31.8  0.001 
Severe GVD at interview 
Yes 0 0.0  1 1.8  4 6.1  2 3.2  7 10.6  0.042 
Pacemaker at interview 
Yes 1 1.9  3 5.3  4 6.1  7 11.3  11 16.7  0.036 
Anticoagulant (Sintrom®) at interview 
Yes 4 7.7  1 1.8  4 6.1  7 11.3  4 6.1  0.340 
Comorbidities at interview 
AHT 
Yes 22 42.3  30 52.6  42 63.6  42 67.7  48 72.7  0.005 
Hyperlipidemia 
Yes 26 50.0  30 52.6  34 51.5  35 56.5  40 60.6  0.769 
Dermatological disease 
Yes 1 1.9  3 5.3  3 4.5  3 4.8  6 9.1  0.513 
Diabetes mellitus 
Yes 16 30.8  17 29.8  17 25.8  13 21.0  29 43.9  0.061 
Urological disease 
Yes 1 1.9  4 7.0     3 4.8  6 9.1  0.098 
Table 2. Clinical characteristics of heart recipients: categorical variables 
 
6 months 
(n = 52) 
 
12 months 
(n = 57) 
 
36 months 
(n = 66) 
 
60 months 
(n = 62) 
 
120 months 




n %  n %  n %  n %  n %  
Neuromuscular disease 
Yes 7 13.5  5 8.8  4 6.1  5 8.1  8 12.1  0.661 
Neoplasm (cutaneous neoplasm, lymphomas, or other solid or hematological malignancies) 
Yes 0 0.0  1 1.8  4 6.1  4 6.5  11 16.7  0.002 
Orthopedic diseases 
Yes 2 3.8  3 5.3  6 9.1  7 11.3  12 18.2  0.068 
                 
 
HTx, heart transplant; SD, standard deviation.  
GVD, graft vascular disease: patient has required a surgical or percutaneous revascularization, or has generated a 
ventricular dysfunction, or has produced heart failure or angina.  
a Chi‐square test (exact test in case of 2 × 2 tables or in case of valid cases <20).  
Table 3. Clinical characteristics of heart recipients: continuous variables 
 
6 months 
(n = 52) 
 
12 months 
(n = 57) 
 
36 months 
(n = 66) 
 
60 months 
(n = 62) 
 
120 months 




Mean SEM  Mean SEM  Mean SEM  Mean SEM  Mean SEM  
                 
Age at HTx 53.49b 1.56  57.04 1.18  55.69 1.35  55.02 1.69  60.20 1.38  0.006 
BMI at HTx 25.27 0.50  25.40 0.54  25.87 0.49  25.23 0.48  25.81 0.51  0.872 
Left ventricular ejection 
fraction at HTx (Eco) (%) 
64.92 1.02  66.34 1.14  64.67 1.22  66.28 1.05  64.00 1.04  0.601 
No. hospital admissions after 
HTx (>24 hrs not scheduled) 
0.32b 0.08  0.83b 0.14  1.09b 0.20  1.03b 0.23  2.09 0.29  0.001 
No. infections requiring 
hospitalization after HTx 
0.23 0.08  0.54 0.12  0.45 0.09  0.44 0.13  0.65 0.14  0.049 
No. episodes of rejection after 
HTx 
0.21b 0.06  0.61b 0.16  0.48b 0.10  0.80 0.15  1.42 0.19  0.001 
Charlson Index at time of 
interview (mean, SD) 
0.50b 0.75  0.73b 1.11  0.71b 1.47  0.64b 1.02  1.42 1.40  0.010 
                 
 
SEM, standard error of the mean; HTx, heart transplant.  
a Kruskal–Wallis test.  
b Bonferroni's correction for 2 × 2 comparisons (significant differences with 120 months group).  
Overall, there were no differences in sociodemographic or economic variables. Regarding their 
clinical profiles, patients had chronic heart disease before HTx (>88% in all groups) and received 
an elective HTx (>74% in all groups). The majority of patients had no limitations in physical 
activity, and there was no objective evidence of cardiovascular disease (NYHA Class I and A, 
respectively). Nevertheless, according to this scale, the percentage of patients with functional 
limitations increased significantly 120 months post‐transplant (Table 2). With respect to the most 
relevant comorbidities, more complications were observed (particularly arterial hypertension and 
diabetes) in the group of patients who had received the allograft 120 months previously (Table 2). 
In addition, mean Charlson Index scores were significantly higher in this group, while patients 
remained fairly stable between 12 and 60 months post‐transplant (Table 2).  
Reported outcomes and multivariate analysis 
The results showed reasonably good levels of patient functioning, well‐being, and social 
support (Table 4) at all stages after transplant. No statistically significant differences were found 
between the different regions in Spain for EQ‐5D utility scores (F3,300 = 1.219, p = 0.303).  
Table 4. Measures of HRQoL, social support, and satisfaction with work status [at interview time] 
 
6 months  12 months  36 months  60 months  120 months  
p 
valuea 
Mean SEM  Mean SEM  Mean SEM  Mean SEM  Mean SEM  
 
KCCQ [HRQoL] (0: worst‐100: best) 
Symptom frequency 87.82 2.25  89.00 2.21  90.34 2.10  87.74 2.50  83.43 2.69  0.104 
Symptom stability 60.10 2.68  54.39 2.18  54.92 2.24  54.17 2.16  59.62 2.61  0.237 
Impact of symptoms 88.94 2.26  90.92 1.88  93.43b 1.73  88.17 2.26  82.44b 2.77  0.010 
Global symptoms 78.95 1.63  78.01 1.47  79.57 1.45  76.83 1.86  75.16 2.07  0.511 
Quality of life 77.72b 2.99  79.82 2.73  88.57b 1.59  85.35 2.39  80.51 2.40  0.017 
Social limitation 81.09 3.23  84.65 2.76  91.57b 2.05  81.18 3.09  78.74b 2.88  0.007 
Physical limitation 83.83 2.68  84.12 2.80  88.57 2.51  83.05 3.23  78.35 2.80  0.005 
Self‐efficacy 87.50 2.85  85.31 2.22  89.39 1.97  84.68 2.10  84.42 2.59  0.207 
OSS 80.46 2.16  81.65 1.92  87.05b 1.30  81.60 2.14  78.27b 1.94  0.030 
CSS 81.39 1.80  81.06 1.77  84.11b 1.54  79.94 2.19  76.79b 1.89  0.026 
EQ‐5D utility index 0.81 0.03  0.82 0.03  0.85 0.03  0.86b 0.02  0.75b 0.03  0.033 
EQ‐5D VAS (0–100) 79.04b 2.01  76.35 2.18  79.48b 1.68  75.34 2.43  68.31b 2.46  0.011 
Duke‐UNC [Social Support] (11–55) 46.77 0.97  46.55 1.12  46.36 0.84  46.36 0.89  45.13 1.03  0.765 
Satisfaction with working status (VAS, 0–
10)c  
7.07 0.79  5.47 0.82  6.31 1.18  5.71 0.76  6.29 0.81  0.638 
                 
 
SEM, standard error of the mean; OSS, overall status summary; CSS, clinical summary score.  
a Kruskal–Wallis test.  
b Bonferroni's correction for 2*2 comparisons.  
c Satisfaction with working status was assessed only by patient who were active (not retired due to disease or age) at 
interview time (total subsample, n = 79).  
However, a slightly higher proportion of patients reported some difficulties in the EQ‐5D 
domains at 120 months post‐transplant (Fig. 1). Caregiver burden was low in all groups (mean 
scores and standard error of the mean, by group): six months: 16.24 (1.61); 12 months: 18.41 
(1.58); 36 months: 16.57 (1.87); 60 months: 14.49 (1.95); and 120 months: 17.07 (1.59); 





Figure 1 Domains of EQ‐5D by study groups. The percentage of patients at all stages after transplant showed good 
punctuation at EQ‐5D (five domains). However, a slightly higher proportion of patients suggested some difficulties in the 
EQ‐5D domains at 120 months post‐transplant. 
 
  
The relationship of clinical and sociodemographic variables with the scores of the instruments 
detailed in Table 4 was also assessed in multivariate analyses to control the possible effect of 
confounding factors (Table 5). With respect to the EQ‐5D utility index and the general domains of 
the KCCQ scores (EQ‐5D utility index: 48.4% of explained variance, F4,164 = 38.46, p < 0.001 and 
OSS: 45% of explained variance, F3,198 = 54.073, p < 0.001), the most related factors were 
comorbidities (neuromuscular and urological disease), hospital admissions, and severe graft 
vascular disease (GVD). All these parameters were negatively associated with utilities and 
HRQoL scores. Female sex was also negatively related to EQ‐5D values, but to a lesser degree. 
Table 5. Variables associated with patients' well‐being and caregivers' burden 
 
B 
CI of B 
Beta p value Tolerance 
Minimum Maximum 
 
EQ‐5D utility index, R2 = 0.484, F4,164 = 38.46, p < 0.001 
OSS 0.008 0.007 0.010 0.585 0.000 0.976 
Neuromuscular disease −0.158 −0.240 −0.075 −0.218 0.000 0.949 
Urological disease −0.183 −0.301 −0.066 −0.174 0.002 0.988 
Sex −0.076 −0.136 −0.016 −0.142 0.014 0.977 
KCCQ‐OSS, R2 = 0.450, F3,198 = 54.073, p < 0.001 
EQ‐5D utility index 43.105 35.557 50.653 0.608 0.000 0.953 
GVD −10.198 −18.219 −2.178 −0.143 0.013 0.853 
Admissions to hospital −1.177 −2.243 −0.112 −0.127 0.031 0.818 
Zarit Caregivers' Burden, R2 = 0.225, F5,168 = 9.44, p < 0.001 
OSS −0.178 −0.280 −0.076 −0.248 0.001 0.922 
Infections requiring hospitalization 2.844 1.024 4.665 0.218 0.002 0.957 
Biopsies post‐transplant −0.646 −1.019 −0.273 −0.243 0.001 0.946 
Resting heart rate 2.883 0.580 5.186 0.172 0.014 0.984 
Duke‐UNC scale −0.299 −0.545 −0.053 −0.173 0.017 0.916 
Duke‐UNC [Social support], R2 = 0.144, F5,168 = 5.49, p < 0.001 
OSS 0.079 0.015 0.142 0.190 0.016 0.872 
Biopsies post‐transplant −0.354 −0.582 −0.126 −0.230 0.003 0.935 
Zarit Caregivers' Burden −0.112 −0.201 −0.023 −0.193 0.014 0.856 
Use of Sintrom −3.894 −7.367 −0.420 −0.164 0.028 0.955 
NYHA objective 1.488 0.009 2.968 0.149 0.049 0.928 
       
 
OSS, overall status summary; GVD, graft vascular disease; CI, confidence intervals. 
 
In contrast, there was no association between time since transplantation and health status. 
Regarding patients' perception of their social network, a very small proportion of variance in the 
Duke scale could be explained by independent variables (14.4%). Finally, considering caregiver 
burden (22.5% of explained variance, F5,168 = 9.44, p < 0.001), the main clinical variables related 
to higher caregiver burden were the total number of infections requiring hospitalization and resting 
heart rate; while OSS scores, number of biopsies, and Duke scale scores were negatively related to 
burden scores.  
  
Discussion 
In line with the recent recommendations for measuring HRQoL in cardiovascular diseases 
(20), a complete evaluation of patients at six, 12, 36, 60, and 120 months post‐transplant was 
carried out by applying generic and disease‐specific instruments.  
 
Overall, the results showed reasonably high levels of patient HRQoL and functioning 
capabilities at all stages post‐transplant. Compared with previous studies conducted in Spain, our 
findings at six and 12 months post‐transplant for the KCCQ questionnaire (both CSS and OSS 
domains) were similar to those published by Ortega et al. (17) in heart recipients. Furthermore, 
mean EQ‐5D VAS scores obtained from our series and that of Ortega et al. (17) were also 
compatible. Regarding later post‐transplantation stages, the high levels of HRQoL reported by 
transplant recipients in our study are consistent with the results from other studies, which reported 
generally stable transplant benefits in terms of high HRQoL satisfaction in patients at 60, 72, and 
120 months post‐transplant (9, 21). However, we found that some difficulties were reported in the 
EQ‐5D domains 120 months post‐transplant. In fact, the VAS values recorded throughout this 
study were similar to those reported in the general Spanish population (22) in all groups, with the 
exception of the 120 months post‐transplant assessment, where scores were lower (23, 24). 
 
After controlling for possible confounding factors in the multivariate analyses, this decrease in 
patient well‐being was not related to age or time since transplant, but rather to the presence of 
comorbid medical conditions, severe GVD, and use of resources (number of hospitalizations). 
Once again, similar conclusions have been reached in previous studies from other developed 
countries (9, 10, 25, 26). 
 
Patient social functioning was adequate, caregiver burden was low, and no differences between 
groups were found in these outcomes. Heart transplantation has been associated in the literature 
with a higher risk of anxiety and depressive disorders in caregivers 36 months after their family 
member's heart transplantation (27), probably exacerbated by uncertainty about the future, 
economic problems, and other causes (28). However, in our series, the burden felt by close 
relatives and professional caregivers was low in all groups. In this case, the significant parameters 
related to this burden included recipient HRQoL, the presence of complications, and social 
support.  
 
This study has a number of limitations that should be addressed. First, it should be noted that 
all outcome measurements were obtained from transplant recipients and their caregivers who were 
willing to participate and complete the questionnaires. Thus, the results obtained from this sample 
may be biased in terms of overestimation or underestimation of HRQoL, social support, and 
caregiver burden. Moreover, the results from the caregiver sample should be treated with caution 
because professional and family caregivers were combined and the basic demographic data of this 
group were not collected. Nevertheless, our results in the early stages are similar to those of a 
longitudinal study also conducted in Spain which followed transplant recipients up to 12 months 
post‐transplant (17). We also appreciate that a longitudinal design would be preferable in order to 
take a closer look at the effect of clinical and sociodemographic variables on dependent variables, 
to quantify the magnitude of effect size, and to produce a methodologically more robust test of the 
stability of perceived benefits. Finally, although the total number of participants was relatively 
large, the smaller size of the subgroups may limit generalization of the results. Nevertheless, 
results at early post‐transplantation stages were consistent with previous publications in our 
country, and the reasonable levels of well‐being reported at later post‐transplantation stages were 
congruent with the evidence of stability from previous longitudinal studies (9, 21). Moreover, 
various variables that were identified as predictive factors of patient HRQoL in other studies (i.e., 
comorbid medical conditions, severe GVD, hospitalizations) (10) were also associated with 
dependent variables in our setting.  
  
In conclusion, outcomes in Spain at all stages after heart transplant seem to be satisfactory, and 
recipients report reasonable levels of HRQoL and social support. Accordingly, their caregivers or 
relatives also report low levels of disruption in their life. 
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